Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21072768 | 0.99 | PARP14 (0.98) | PARP14 | |
| SCHEMBL21073004 | 0.94 | PARP14 (1.00) | PARP14 | |
| SCHEMBL21073095 | 0.92 | PARP14 (0.84) | PARP14 | |
| SCHEMBL29443232 | 0.92 | PARP14 (0.84) | PARP14 | |
| SCHEMBL24923298 | 0.89 | PARP14 (0.83) | PARP14 | |
| SCHEMBL29443266 | 0.89 | PARP14 (0.83) | PARP14 | |
| SCHEMBL24923127 | 0.89 | PARP14 (0.85) | PARP14 | |
| SCHEMBL21071698 | 0.89 | PARP14 (0.83) | PARP14 | |
| SCHEMBL24923015 | 0.88 | PARP14 (0.81) | PARP14 | |
| Hydrochloric Acid SCHEMBL31483813 | 0.88 | PARP14 (0.81) | PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | claimed |
| EP-4284376-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | Ribon Therapeutics Inc. (US) | 2023-12-06 | — | — | EP | claimed |
| CN-117136060-A | Methods of treating inflammatory diseases | 里邦医疗公司 | 2023-11-28 | — | — | CN | claimed |
| EP-3728207-B1 | QUINAZOLINONES AS PARP14 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | claimed |
| US-20230018702-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2023-01-19 | — | — | US | claimed |
| US-20220265655-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | ABBVIE BIOTECHNOLOGY LTD (BM) | 2022-08-25 | — | — | US | claimed |
| WO-2022165118-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | RIBON THERAPEUTICS, INC. (US) | 2022-08-04 | — | — | WO | claimed |
| EP-3728207-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | Ribon Therapeutics Inc. (US) | 2020-10-28 | — | — | EP | claimed |
| US-20190194174-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2019-06-27 | — | — | US | claimed |
| US-20260125362-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2026-05-07 | — | — | US | disclosed |
| EP-4284376-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | Ribon Therapeutics Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-117136060-A | Methods of treating inflammatory diseases | 里邦医疗公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-4212515-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-4212515-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2020257416-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| EP-3728207-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | Ribon Therapeutics Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| CN-111699176-A | Quinazolinones as PARP14 inhibitors | 里邦医疗公司 | 2020-09-22 | — | — | CN | disclosed |
| US-20200247788-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2020-08-06 | — | — | US | disclosed |
| US-10562891-B2 | Quinazolinones as PARP14 inhibitors | Ribon Therapeutics Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190194174-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | PARP14 1/4885 |
| US-20200247788-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | PARP14, PARP15, PARP11 | PARP14 1/4885 |
| US-10562891-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | PARP14 1/4885 |
| US-20230018702-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | PARP14, PARP15, PARP11 | PARP14 1/4885 |
| US-20220265655-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | PARP14, PARP4, PARP12 | PARP14 1/4885 |
| US-20190194174-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | PARP14, PARP15, PARP11 | PARP14 1/4885 |
| US-20260125362-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP16, PARP11 | PARP14 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.